SEC Form 4 · accession 0001192482-17-000048
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garry Arthur Neil
Officer — Chief Scientific Officer
Period of report
Feb 17, 2017
Accepted (ET)
Feb 17, 2017 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $4.91 | Feb 17, 2017 | A | 200,000 | A | — | Feb 17, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on February 17, 2018, February 17, 2019 and February 17, 2020, subject to the reporting person's continued service with the issuer.